Amgen Q2 revenue rises 10% to $10.1 billion; non-GAAP EPS up 4% to $6.29
Amgen reported second-quarter 2026 results on August 4, 2026, with total revenues up 10% to $10.1 billion and non-GAAP EPS up 4% to $6.29. The company also issued full-year 2026 guidance of $38.2 billion to $39.4 billion in total revenues and non-GAAP EPS of $22.30 to $23.50. Product sales were mixed: Repatha, Evenity and Tezspire grew strongly, while Prolia and Otezla declined.
Key points
- GAAP EPS rose 65% to $4.37 from $2.65, and GAAP operating income rose to $3.5 billion from $2.7 billion.
- Non-GAAP operating margin was 48.4%, down 0.5 percentage points from a year earlier.
- Free cash flow was $3.5 billion versus $1.9 billion, and the company made no share repurchases in the quarter.
- Prolia sales fell 32% to $759 million, while Repatha sales rose 37% to $953 million.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.